• Users Online: 284
  • Print this page
  • Email this page

    Article Cited by others


Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension

Amin Ahmad, Mohamadifar Arezoo, Taghavi Sepideh, Naderi Nasim, Sadeghi Hosnolah

Year : 2015| Volume: 4| Issue : 3 | Page no: 7-7

   This article has been cited by
1 Organbadversuche an humanen Pulmonalgefäßen: Beurteilung der Medikamentenwirkung zur Behandlung der pulmonalarteriellen Hypertonie
C. Stadlbauer,S. Golovchenko,L. Englert,M. Spaeth,M. Hoenicka,H.-S. Hofmann,M. Ried
Pneumologie. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis
Lopamudra Kirtania,Rituparna Maiti,Anand Srinivasan,Archana Mishra
Clinical Drug Investigation. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
Su-Gang Gong,Lan Wang,Bigyan Pudasaini,Ping Yuan,Rong Jiang,Qin-Hua Zhao,Jing He,Rui Zhang,Wen-hui Wu,Jin-Ming Liu,Cai-cun Zhou
Canadian Respiratory Journal. 2018; 2018: 1
[Pubmed]  [Google Scholar] [DOI]


Read this article